Ultragenyx settles DOJOLVI patent litigation; Esjay generic entry set for 2033

Ultragenyx Pharmaceutical Inc.

Settlement with Esjay resolves ANDA patent suit over DOJOLVI (triheptanoin) in NJ district court.
Esjay gets non-exclusive royalty-free license to market generic DOJOLVI starting Jan 1, 2033, or Jul 1, 2033 if pediatric exclusivity granted.
Other DOJOLVI ANDA patent suits against other filers remain pending in same court.
Settlement to be submitted to FTC and DOJ as required by law.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.